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Proteomics reveals ablation of 
PlGF increases antioxidant and 
neuroprotective proteins in the 
diabetic mouse retina
Madhu Sudhana Saddala1, Anton Lennikov  1,4, Dennis J. Grab5,6, Guei-Sheung Liu  7, 
Shibo Tang2,3 & Hu Huang1,2,3
Placental growth factor (PlGF or PGF), a member of the vascular endothelial growth factor (VEGF) sub-
family, plays a crucial role in pathological angiogenesis and inflammation. However, the underlying 
molecular mechanisms that PlGF mediates regarding the complications of non-proliferative diabetic 
retinopathy (DR) remain elusive. Using an LC-MS/MS-based label-free quantification proteomic 
approach we characterized the alterations in protein expression caused by PlGF ablation in the retinas 
obtained from C57BL6, Akita, PlGF−/− and Akita.PlGF−/− mice. After extraction and enzymatic 
digestion with Trypsin/LysC, the retinal proteins were analyzed by Q-Exactive hybrid Quadrupole-
Orbitrap mass spectrometry. Differentially expressed proteins (DEPs) were identified in four 
comparisons based on Z-score normalization and reproducibility by Pearson’s correlation coefficient. 
The gene ontology (GO), functional pathways, and protein-protein network interaction analysis 
suggested that several proteins involved in insulin resistance pathways (Gnb1, Gnb2, Gnb4, Gnai2, 
Gnao1, Snap2, and Gngt1) were significantly down-regulated in PlGF ablated Akita diabetic mice 
(Akita.PlGF−/− vs. Akita) but up-regulated in Akita vs. C57 and PlGF−/− vs. C57 conditions. Two proteins 
involved in the antioxidant activity and neural protection pathways, Prdx6 and Map2 respectively, 
were up-regulated in the Akita.PlGF−/− vs. Akita condition. Overall, we predict that down-regulation 
of proteins essential for insulin resistance, together with the up-regulation of antioxidant and 
neuroprotection proteins highlight and epitomize the potential mechanisms important for future anti-
PlGF therapies in the treatment of DR.
Diabetic retinopathy (DR), a sight-threatening microvascular complication of diabetes myelitis (DM), remains 
the leading cause of vision loss world-wide in the adult population, especially in economically developed coun-
tries1. With the increasing number of people with DM, the prevalence of DR and diabetic macular edema (DME) 
is expected to grow2. Metabolic changes in the diabetic retina result in the altered expression pattern of several 
growth factors, neurotrophic factors, cytokines/chemokines, vasoactive agents, and inflammatory and adhesion 
molecules, resulting in vascular lesions and cell death3–5. Emerging evidence suggests that retinal neurodegen-
eration is an early event in the pathogenesis of DR, which could participate in the development of microvascular 
abnormalities6,7.
Placenta growth factor (PlGF) is a member of vascular endothelial growth factor (VEGF) family proteins that 
were first discovered in human placental cDNA in 19918. Over two decades of scientific research and develop-
ment have increased our understanding of the PlGF biological function. Despite the high level of expression in 
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the placenta, the ablation of PlGF in mice did not compromise the healthy embryonic development or adverse 
postnatal health effects9. Delivery of recombinant PlGF homodimer, PlGF-VEGFA heterodimer significantly pro-
moted angiogenesis in ischemic conditions through FLT110. Furthermore, many other cell types express PlGF 
in pathological conditions, including retinal pigment epithelial cells (RPE)11. This up-regulation is due not only 
to hypoxia but to responses to other stimuli including nitric oxide12, cytokines, such as interleukin-1 (IL-1), 
TNF-α13 and transforming growth factor-β1 (TGF-β)14. The observation that endothelial cells over-express PlGF 
under pathological angiogenesis conditions has also been confirmed15.
We reported that deleting PlGF in a C57BL/6-Ins2Akita/J (Akita) mouse line containing a dominant muta-
tion induces spontaneous rapid onset diabetes16. In the retina, ablation of PlGF in the diabetic mice resulted in a 
decreased expression of diabetes-activated hypoxia-inducible factor (HIF)1α. Changes in VEGF pathway includ-
ing expression of HIF1α, VEGF, VEGFR1–3, and levels of phospho (p)-VEGFR1, p-VEGFR2, and p–endothelial 
nitric oxide synthase in the retinas of diabetic PlGF−/− mice, were also found. These changes occur without any 
noticeable effect on glucose balance or expression of intercellular adhesion molecule-1, vascular cell adhesion 
molecule-1, CD11b, and CD1817.
With much still to be learned regarding the biological roles of PlGF in DR, the transition from animal to 
human studies is currently underway in the form of 2phase II clinical trials designed to assess the therapeu-
tic use of two anti-PlGF recombinant monoclonal antibodies in human DR patients: i.e., NCT03071068 and 
NCT03499223 (ThromboGenics, 2018)18,19. While the use of blocking PlGF antibodies for proteomic scale studies 
in humans is possible they are not without challenges.
Here we introduce a quantitative proteomic analysis approach based on label-free mass spectrometry (LFMS) 
to elucidate the beneficial role and molecular mechanisms of PIGF in DR using PIGF knockout mice. The study is 
based on retinal protein extracts from three genetically modified mouse strains with diabetic and PIGF knockout 
backgrounds. The advantages of LFMS for protein identification and quantification allowed a gel-free method 
without the use of isotopic labeling20. Furthermore, as DR affects the expression of many commonly used “house-
keeping” proteins such as ACTB and Tubulin, an added advantage of the LDMS is that the number of peptide 
sequences rather than any relative quantification identifies proteins21,22, To date we have identified 3176 total 
proteins of which 107 were significantly different between the experimental group combinations tested (p < 0.05).
Results
Animals and diabetic conditions. With four animals per study group, we monitored the body weight and 
blood glucose levels in control C57 (PlGF+/+) and Akita, Akita.PlGF−/− and PlGF−/− mice on a C57 background 
(Fig. 1). When compared to the C57 control animals of the same age, diabetic Akita mice demonstrated signifi-
cant increases in blood glucose (BG) levels (p < 0.001) accompanied by decreases in body weight (p < 0.01). In 
contrast, no significant changes were found in blood glucose (p > 0.05) level or body weight (p > 0.05) in mice 
lacking PlGF; i.e., compare Akita.PlGF−/− vs. Akita or PlGF−/− vs. C57. Retinal protein fractions from all four 
conditions were also prepared LC/MS/MS analysis (below).
Label-free proteomics data analysis. The MaxQuant framework was used for proteomics data analysis, 
which is written in C# in the Microsoft.NET environment. Algorithmic sets of MaxQuant are freely accessible 
as source code, and the complete program (http://www.maxquant.org). We followed detailed instructions for 
installation and supporting programs by Cox et al.23. The four experimental data sets (Akita.PlGF−/−, PlGF−/−, 
Akita, and C57) were taken as a raw files for label-free quantification using MaxQuant version 1.6.01 (http://max-
quant.org/). The overall proteomics data analysis workflow is represented in Fig. 2. From the dataset, MaxQuant 
calculated the number of quantified proteins, peptides, and sites. A total of 200102 msmsScans, 88071 msScans, 
5990710 peaks, 465 oxidation(M)Sites, 668368 peptides and 794 proteins were identified (FDR < 0.01) along with 
mass, m/z, scans, and peaks, etc., for all data sets in the combined/text folder of the MaxQuant output directory.
Perseus analysis pipeline. Perseus is software for shotgun proteomics data analysis, which helps to extract 
biologically meaningful information from processed raw files. It performs Bioinformatics analyses of the output 
of MaxQuant, and thus completes the proteomics analysis pipeline, allowing easy integration of an unlimited 
number of independent statistical tools, which can thus be combined in an analysis24. The experimental sample 
datasets (n = 4) were considered for statistical analysis: Akita.PlGF−/− vs. Akita, Akita vs. C57, PlGF−/− vs. C57 
and Akita.PlGF−/− vs. PlGF−/−. Because of Akita.PlGF−/− was derived from PlGF−/− background, whereas Akita 
from C57BL/6J, Akita. PlGF−/− was not compared to C57, nor Akita to PlGF−/− because the findings may be 
affected by the animal genetic background difference.
We determined that the LFQ (Label-Free Quantification) intensity of all combinations and intensity average 
be the same for all the samples and without bias. The correlation coefficient of LFQ intensities of the biological 
replicates was higher than 0.839. For the Akita.PlGF−/− vs. Akita combination there was 0.839 low LFQ intensities 
between Akita.PlGF−/− replicate 1 and Akita replicate 3, 0.937 high LFQ intensities between Akita.PlGF−/− rep-
licates 1 and 2. In Akita vs., C57 combination, 0.867 low LFQ intensities between Akita replicate four and C57 
replicate 2, 0.943 high LFQ intensities between C57 replicates 3 and 4. In PlGF−/− vs. C57 combination 0.876 low 
LFQ intensities between PlGF−/− replicate 1 and C57 replicate 3, 0.945 high LFQ intensities between PlGF−/− 
replicates 2 and 4. In Akita.PlGF−/− vs. PlGF−/− combination 0.877 low LFQ intensities between Akita.PlGF−/− 
replicate 1 and 3, 0.948 high LFQ intensities between PlGF−/− replicates 2 and 4, suggesting that the experiment 
has high repeatability and reliability (Suppl. Figs 1D, 2D, 3D and 4D). The hierarchical clustering analysis showed 
various components (Suppl. Figs 1A, 2A, 3A and 4A).
Differentially expressed proteins (DEPs) are screened for all combinations mentioned above based on 
fold-change (FC) >2 and p-value < 0.05.
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The Akita.PlGF−/− vs. Akita, combination has 31 DEPs: 6 up-regulated proteins, and 25 down-regulated 
proteins (Suppl. Table 2). The Akita vs. C57 combination has 26 DEPs: 15 up-regulated proteins and 11 
down-regulated proteins (Suppl. Table 3). The PlGF−/− vs. C57 combination has 31 DEPs: 15 up-regulated 
proteins and 16 down-regulated proteins (Suppl. Table 4). The Akita.PlGF−/− vs. PlGF−/− combination has 19 
DEPs: 6 up-regulated proteins and 13 down-regulated proteins (Suppl. Table 5). All the comparisons of up and 
down-regulated proteins were represented as a heat map (Figs 3A, 4A, 5A and 6A). The DEPs of all combinations 
are used for gene annotation (GO) and pathways analysis.
Functional classification and pathway analysis. The DEPs of all combinations were uploaded to the 
DAVID annotation tool using the complete mouse proteome as background. The GO terms were predicted 
based on Expression Analysis Systematic Explorer (EASE) < 0.1 and threshold count (TC) ≥ 2. The molec-
ular functions, biological processes, cellular components protein classes, and pathways were predicted in the 
significantly-enriched GO terms of up and down-regulated proteins. The gene ontology functions identified for 
the DEPs in the Akita.PlGF−/− vs. PlGF−/− combination included biological processes (BP), molecular func-
tions (MF), cellular components (CC), and protein classes and Reactome pathways. For biological processes, 
27% of the proteins were predicted to be involved in cellular processes (GO:0032502) with another 24% in the 
metabolic process (GO:0008152) (Fig. 3B). In molecular functions, 47% and 31% of proteins were predicted to 
have binding (GO:005488) and catalytic activity (GO:003824), respectively (Fig. 3C). In cellular components, 48% 
of proteins belonged to the cell part (GO:0044464) (Fig. 3D). Another 26% and 19% of proteins had to do with 
nucleic acid binding (PC00171) and enzyme modulation (PC00095), respectively (Fig. 3E). Proteins involved in 
various Reactome biological pathways, included G-protein activation pathway, regulation of insulin secretion 
pathway and others were also found (Fig. 3F).
For the DEPs of Akita vs. C57 combination, involvement in various molecular functions, biological processes, 
cellular components, protein classes, and Reactome pathways were predicted.
For the biological process 30% and 22% of proteins were linked to cellular (GO:0009987) and metabolic 
(GO:0008152) processes respectively (Fig. 4B). Regarding molecular functions, 48% of the proteins were catalytic 
Figure 1. (A) Graphical representation of the animal breeding program; (B) screening of diabetic conditions; 
(C) retinal sample collection, (D) initial preparation of peptide digests. Artwork design by Dmitry Rumyancev 
(dmitry_r75@mail.ru). Copyright transferred to Macmillan Publishers Ltd, part of Springer Nature, under an 
open-access license Attribution 4.0 International (CC BY 4.0).
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(GO:0003824), 19% had binding (GO:0005488), 19% transporter activity (GO:0005215) and other activities 
(Fig. 4C). Also, 37% of proteins belonged to the cell part (GO:0044464), 31% proteins belong to the macromo-
lecular complex (GO:0032991) and others in cellular components (Fig. 4D). 31%, 22% of proteins belong to 
hydrolase (PC00121), transporter (PC00227) and other classes (Fig. 4E). The proteins are involved in mostly 
unclassified pathways, regulation of insulin secretion, transmission across chemical synapses and neuronal sys-
tem pathways respectively (Fig. 4F).
The DEPs of PlGF−/− vs. C57 combination is involved in various molecular functions, biological processes, 
cellular components, protein classes, and biological pathways. 29%, 18% of proteins are involved in various bio-
logical processes, such as cellular process (GO:0009987), metabolic process (GO:0008152) and other functions 
(Fig. 5B). 45% and 34% of proteins are involved in binding (GO:0005488), catalytic activity (GO:0003824) and 
other functions of molecular functions (Fig. 5C). The proteins are mainly involved in the cellular component pro-
cess such as cell part (GO:0044464), macromolecular complex (GO:0032991) and organelle (GO:0043226) with 
Figure 2. The overall workflow of our proteomics data analysis. The mass spectral (MS) raw data were analyzed 
with MaxQuant computational proteomics platform and its built-in Andromeda search engine. Artwork design 
by Dmitry Rumyancev.
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31%, 27% and 22% respectively (Fig. 5D). Most proteins (39%) belong to nucleic acid binding (PC00171) protein 
class (Fig. 5E). Reactome pathways results show that the proteins involved in activation of the phototransduction 
cascade, signal transduction, G-protein activation, adrenaline, noradrenaline inhibit insulin secretion and regu-
lation of insulin secretion pathways (Fig. 5F).
The DEPs of Akita.PlGF−/− vs. PlGF−/− combination is involved in the various biological processes such 
as cellular process (GO:0009987) (29%), metabolic process (GO:0008152) (23%) and cellular component 
organization or biogenesis (GO:0071840) (17%) respectively (Fig. 6B). 57%, 19% of proteins are involved in 
binding (GO:0005488) and structural molecule activity (GO:0005198) in molecular functions (Fig. 6C). The 
proteins are mainly involved in the cellular component process such as cell part (GO:0044464) and organelle 
(GO:0043226) with 41% and 35% respectively (Fig. 6D). In protein class, 24% of proteins belong to cytoskeletal 
proteins (PC00085), 19% of proteins belong to nucleic acid binding (PC00171) proteins and others (Fig. 6E). The 
Reactome pathway results indicate that DEPs are involved in organelle biogenesis and maintenance, translocation 
of GLUT4 to the plasma membrane, Hedgehog ‘off ’ state and Hedgehog ‘on’ state (Fig. 6F).
Protein-protein network analysis. The DEPs of Akita.PlGF−/− vs. Akita have been uploaded to 
STRING network. The network results showed that DEPs have total 30 nodes, 26 edges, cluster coefficient 
0.497, average node degree:1.73, PPI enrichment p-value:1.17e-05 and involved in complex protein assembly 
Figure 3. Functional annotation, Reactome pathways and protein-protein interaction network of Akita.
PlGF−/− vs. Akita. (A) Significantly up and down-regulated proteins were represented as a heat map. (B) The 
differentially expressed proteins (DEPs) are involved in the different biological process. (C) The differentially 
expressed proteins (DEPs) are involved in different molecular functions. (D) The DEPs are involved in various 
cellular components functions. (E) The DEPs are different classes of proteins. (F) The DEPs are involved in 
various Reactome biological pathways. (G) Highlighted are the various colors of DEPs involved in complex 
protein assembly (yellow) in a biological process, binding (blue) function of molecular function, membrane-
bounded organelle (red) proteins in cellular component respectively.
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(yellow) in biological process (GO:0006461), binding (blue) function of molecular function (GO:0005488), 
membrane-bounded organelle (red) proteins in cellular component (GO:0043227) (Fig. 3G). The DEPs of Akita 
vs. C57 have total 28 nodes, 27 edges, cluster coefficient 0.539, average node degree:1.73, PPI enrichment p-value: 
2.62e-05 and involve in nervous system development (GO:0007399) (red), response to glucose (GO:0009749) 
(blue) of biological process, catalytic activity (GO:0003824) (light green), hydrolase activity (GO:0016787) (pink) 
of molecular functions, Insulin secretion (ko04911) (yellow), Pancreatic secretion (ko04972) (cyan), Oxidative 
phosphorylation (ko00190) (thick green) of KEGG pathways (Fig. 4G). The DEPs of PlGF−/− vs. C57 have total 
40 nodes, 87 edges, cluster coefficient 0.692, average node degree:4.35, PPI enrichment p-value: 9.93e-10 and 
involve in nervous system development (GO:0007399) (red), eye photoreceptor cell differentiation (GO:0001754) 
(blue) of biological process, hydrolase activity (GO:0016787) (light green), catalytic activity (GO:0003824) (yel-
low) of molecular functions, photoreceptor inner segment (GO:0001917) (pink), photoreceptor outer segment 
(GO:0001750) (thick green) of cellular components, Ras signaling pathway (ko04014) (cyan), VEGF signaling 
pathway (ko04370) (orange), Oxidative phosphorylation (ko00190) (magenta) of KEGG pathways (Fig. 5G). The 
up and down-regulated proteins of Akita.PlGF−/− vs. PlGF−/− have total 19 nodes, 14 edges, cluster coefficient 
0.511, average node degree:1.47, PPI enrichment p-value: 0.0013 and involve in protein folding (GO:0006457) 
(blue) of biological process, binding (GO:0005488) (red) of molecular function, intracellular organelle part 
(GO:0044446) (green) of cellular component, Gap junction (ko04540) (green) of KEGG pathway (Fig. 6G).
Figure 4. Functional annotation, Reactome pathways and protein-protein interaction network of Akita vs. C57. 
(A) Significantly up and down-regulated proteins were represented as a heat map. (B) The DEPs are involved 
in different biological processes. (C) The DEPs are involved in various molecular functions. (D) The DEPs are 
involved in various cellular components. (F) The DEPs are involved in various Reactome biological pathways. 
(G) Highlighted is the various colours of DEPs involved in nervous system development (red), response to 
glucose (blue) of biological process, catalytic activity (light green), hydrolase activity (pink) of molecular 
functions, insulin secretion (yellow), pancreatic secretion (cyan), oxidative phosphorylation (thick green) of 
KEGG pathways.
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The Venn diagrams showed that Akita vs. C57 had 30 DEPs, 20 (26.3%) proteins were unique, and 9 (11.8%) 
proteins were shared with PlGF−/− vs. C57, only one (1.3%) protein was shared with other two groups. Akita. 
PlGF−/− vs. Akita had 15 specific proteins, 3 proteins were shared with PlGF−/− vs. C57, and one protein is shared 
with the other two groups (Fig. 7). We also provided the MS/MS spectrum and the confidently identified peptide 
components of Gnb1, Gnb2, Prdx6 and Map2 proteins (Suppl. Fig. 5).
Discussion
In this study, we examined retinal proteome of the four mouse strains (Akita.PlGF−/−, Akita, C57, and PlGF−/−) 
using the label-free LC-MS/MS-based proteomics approach in order to understand better the molecular mech-
anisms that PlGF mediates in the complications of non-proliferative DR (NPDR). Using normalization by 
the Z-score method and correlation by the Pearson correlation coefficient we characterized the differentially 
expressed proteins (DEPs) between Akita.PlGF−/− and Akita (31 proteins), Akita and C57 (26 proteins), PlGF−/− 
and C57 (31 proteins), Akita.PlGF−/− and PlGF−/− (19 proteins). Given that the complete retinal protein extracts 
Figure 5. Functional annotation, Reactome pathways and protein-protein interaction network of PlGF−/− vs. 
C57. (A) Significantly found up and down-regulated proteins were represented as a heat map. (B) The DEPs are 
involved in different biological processes. (C) The DEPs are involved in various molecular functions. (D) The 
DEPs are involved in various cellular components functions. (E) The DEPs are classified into various protein 
class. (F) The differentially expressed proteins are involved in various Reactome biological pathways. (G) 
Highlighted is the various colours of DEPs involved in nervous system development (red), eye photoreceptor 
cell differentiation (blue) of biological process, hydrolase activity (light green), catalytic activity (yellow) of 
molecular functions, photoreceptor inner segment (pink), photoreceptor outer segment (thick green) of cellular 
components, Ras signalling pathway (cyan), VEGF signalling pathway (orange), oxidative phosphorylation 
(magenta) of KEGG pathways.
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obtained from normal, diabetic and genetically manipulated mice were used for proteome analysis, it is possible 
these DEPs present any retinal cell types. Furthermore, given that ablation of PlGF in the transgenic mice pro-
vides the retinal protection against diabetic damages it is possible that these DEPs are involved in the protective 
retinal phenotypes as previously observed in Akita.PlGF−/− mice. We highlight and discuss several relevant pro-
tein categories including insulin resistance pathway, antioxidant, cytoskeleton, chaperone, and neural protection.
The insulin resistance pathway proteins including Nucleotide Binding proteins (Gnb1, Gnb2, Gnb4, Gnai2, 
Gnao1), Snap25, Stxbp1, and Gngt1 are down-regulated due to PlGF ablation in Akita diabetics (Akita.PlGF−/− 
vs. Akita) but up-regulated in Akita vs. C57. Gnb1, Gnb2, Gnb4, Gnai2, Gnao1 are classified as G-proteins that 
play a crucial role in the insulin signaling pathway. Incessant activation of G-proteins (polymorphism) results 
in insulin resistance and ultimately increases hepatic glucose output. Gnb gene dimorphism leads to increased 
cardiac potassium channel activity and α-adrenoceptor–mediated vasoconstriction thus resulting in the devel-
opment and progression of hypertension, obesity, and insulin resistance in humans25,26. Gnb1, Gnb2, and Stxbp1 
involved in regulation of insulin secretion pathway are up-regulated in Akita compared to the C57 group, the 
condition of which causes insulin resistance.
The role that down-regulation of synaptosomal-associated protein 25 (Snap25) found between the Akita.
PlGF−/− versus the Akita groups play in diabetes is suggested from literature. There is evidence that reduced 
expression of exocytotic genes (Stxbp1 and Snap25) leads to impaired insulin secretion27. On the other hand, 
the lowering of the trans-SNARE complex Snap25 involved in directly executing membranes fusion processes 
between the synaptic vesicle and plasma membranes appear to be associated with enhancement of insulin 
Figure 6. Functional annotation, Reactome pathways and protein-protein interaction network of Akita.
PlGF−/− vs PlGF−/−. (A) Significantly up and down-regulated proteins were represented as a heatmap. (B) The 
DEPs are involved in different biological processes. (C) The DEPs are involved in various molecular functions. 
(D) The DEPs are involved in various cellular components. (F) The DEPs are involved in various Reactome 
biological pathways. (G) Highlighted the various colors of DEPs involved in protein folding (blue) of biological 
process, binding (red) of molecular function, intracellular organelle part (green) of cellular component, Gap 
junction (green) of KEGG pathways.
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secretion28. These stimulatory and inhibitory influences may also involve the physical interaction of Snap25 with 
L-Type Ca2+ channels in β cells29. Our mass spectral results support the findings including the down-regulation 
of plasma membrane calcium-transporting ATPase1 (Atp2b1 protein)29.
Diabetes is often associated with increased oxidative stress and low energy levels that contribute to neuron 
microtubule meshwork degeneration, events that eventually leads to neuron apoptosis30–32. The up-regulation of 
several antioxidant and neural protection pathway proteins in the Akita.PlGF−/− compared to Akita conditions 
is an intriguing and potentially important finding. The oxidoreductase class protein Peroxiredoxin-6 (Prdx6) is 
expressed in the majority of mammalian cells33. In the retina, solely Müller cells and astrocytes that play a cru-
cial role in the maintenance of blood-retinal barrier function express Prdx6. Further, decreased Prdx6 has been 
reported in several disease conditions where the blood-retinal barrier is compromised. These include diabetic 
retinopathy (DR), exudative age-related macular degeneration (AMD) as well as arterial and venous occlusions34.
Tubb6 is the class of cytoskeletal protein that serves as a structural molecule and has the activities of binding, 
organization/biogenesis, and cellular process. Tubb6 allows cells to modify the organization of microtubules, 
regardless of the presence or absence of dystrophin, for the guidance and proper organization of microtu-
bules35. Hsp90ab1 is the chaperone class protein that binds to other proteins, thereby stabilizing them in an 
ATP-dependent manner36.
Microtubule-associated proteins encoded by the Map2 gene are reported to comprise during microtubule 
assembly, a crucial step in the process of neurite formation. In rodents, Map2 are neuron-specific cytoskeletal 
proteins that determine and stabilize dendritic shape throughout neuron development37. Increased production 
of IL-1 beta (IL-1β), IL-6, or TNF-α decreases the Map2 expression and leads to neuronal cell death. Map2 
upregulation increases neuronal cell survival and differentiation. Map2 also serves to stabilize microtubules (MT) 
growth by cross-linking microtubules with intermediate filaments as well as serve as a binding domain for the 
regulatory subunit II of cAMP-dependent protein kinase (PKA).
Conclusion
Our results suggest that reduced insulin resistance in the Akita.PlGF−/− mouse is potentially associated with 
the regulation of the Gnb family of proteins and P-type ATPases. This is important considering the role of these 
molecular players in regulating cell metabolism that allows retinal cells to better utilize glucose by reducing met-
abolic stress and ROS production. The data highlight significant roles for the neuron survival protein (Map2) and 
antioxidant defense protein (Prdx6) as well as roles for Tubb and Hsp protein that potentially increases retinal cell 
survival. Further functional studies are currently being done to identify other candidate proteins and the path-
ways involved to further explore the molecular mechanism of PlGF function and its target and off-target effects. 
Overall, how all the above molecular players intertwine in the end to accent the beneficial effects of targeting 
PIGF is a basis for future research.
Materials and Methods
The Mouse Strains. We used C57BL/6J [C57] mice (PlGF+/+ control] and Akita [C57BL/6-Ins2 < Akita >/J], 
Akita.PlGF−/− [C57BL/6-Ins2 < Akita > /J.PlGF−/−] and PlGF−/− [C57BL/6-PlGF−/−] mice were generated and 
maintained as previously described38. Briefly, Akita mice were crossed with PlGF−/− mice39 in a C57BL/6J back-
ground for two generations to give birth to the progeny with the genotype of Akita.PlGF−/− (Fig. 1A). The use 
of animals complied with the Association for Research in Vision and Ophthalmology (ARVO) statement for 
the use of animals in Ophthalmic and Vision Research and approved by the Institutional Animal Care and Use 
Committee of the Johns Hopkins University (Protocol number: M016M480). Mice were housed at the special 
pathogen-free (SPF) Cancer Research Building animal facilities at Johns Hopkins Hospital.
Figure 7. Comparisons of each group of the DEPs were illustrated by Venn diagrams. (A) The three groups of 
unique DEPs were represented as a Venn diagram. (B) The four groups of unique DEPs were represented as a 
Venn diagram.
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Verification of diabetic conditions. Diabetic phenotypes were confirmed 4.5 weeks after birth by blood 
glucose >250 mg/dL (One-Touch Lifescan meter; Lifescan, Inc., Milpitas, CA) in a drop of blood from a tail 
puncture. Final blood glucose concentration and body weight were measured before sacrifice (Fig. 1B).
Retinal samples collection. Mice were euthanized by intraperitoneal injection with ketamine hydrochlo-
ride (100 mg/kg body weight) and xylazine (4 mg/kg body weight). Mouse eyes were enucleated and the retinas 
carefully isolated free of the cornea, lens, vitreous humor and retinal pigment epithelium (RPE) on ice in cold 
phosphate-buffered saline (PBS, 0.1 M, pH = 7.2) under the dissection microscope (Stemi 2000-C, Zeiss). Retinas 
were snap-frozen with liquid nitrogen and then stored at −80 °C until further use.
Protein extraction and peptide preparation. Retinas were homogenized in RIPA buffer (R0278-50ML; 
Sigma) supplemented with protease and phosphates inhibitor cocktail (Cell Signaling Technology). The retinal 
homogenates were centrifuged (12,000 g, 4 °C, 10 min) to remove tissue debris. The protein concentration of 
the supernatant was determined using Pierce BCA protein assay kit (Thermo Fisher Scientific, Cat#: 23225); 
50-microgram of total protein from each sample was used for peptide preparation (Fig. 1C). DTT reduced pro-
teins were alkylated by iodoacetamide (10 mM, in 50 mM Tris-HCl, pH8.0) at room temperature for 1 h. The 
protein samples were then digested with trypsin/LysC (Fig. 1D) (Promega, Cat#: V5073) in 25 mM ammonium 
bicarbonate solution at 37 °C for 12 h. The resultant peptides were washed and desalted with the desalting column 
(Pierce Spin-Tip) and eluted with 50 µl 5% acetonitrile +0.4% trifluoroacetic acid. The peptides mixtures were 
run through the ziptip C18 (Millipore) and then dried with SpeedVac concentrator.
Mass spectrometry. The LC/MS/MS analyses of samples were carried out using a Thermo Scientific 
Q-Exactive hybrid Quadrupole-Orbitrap Mass Spectrometer and Thermo Dionex UltiMate 3000 RSLCnano 
System (Poolchon Scientific, Frederick, MD, USA). Peptide mixtures from each sample were loaded onto a pep-
tide trap cartridge at a flow rate of 5 μL/min. The trapped peptides were eluted onto a reversed-phase PicoFrit 
column (New Objective, Woburn, MA) using a linear gradient of acetonitrile (3–36%) in 0.1% formic acid. The 
elution duration was 120 min at a flow rate of 0.3 μl/min. Eluted peptides from the PicoFrit column were ionized 
and sprayed into the mass spectrometer, using a Nanospray Flex Ion Source ES071 (Thermo) under the following 
settings: spray voltage, 1.6 kV, capillary temperature, 250 °C.
Label-free proteomics data analysis. The mass spectral (MS) raw data were analyzed using the MaxQuant 
computational proteomics platform (version 1.6.1.0) and its built-in Andromeda search engine40. The LTQ-Orbitrap 
peptides were identified (main search peptide search = 4.5 ppm and 20 ppm for first search peptide tolerance, 
respectively) from the MS/MS spectra searched against the Mus musculus UniProtKB (83,598 entries) target 
database41 using the Andromeda search engine42.
This target database was also shared with the common contaminants and concatenated with the reversed ver-
sions of all sequences. In group-specific parameters, enzyme-specific was set to trypsin, and two missed cleavages 
were allowable; variable modifications were selected as fixed modification whereas carbamidomethylation (C) 
and oxidization (M) were set as fixed and variable modifications respectively were selected as variable modifica-
tions and 5 set to a maximum number of modifications per peptide. The type was set the standard; multiplicity 
was set to 1 to account for the label-free state, and label-free quantification was set LFQ, 2 set for minimum ration 
count40. The FDR was set to 0.01 for proteins, peptides and other parameters were set to default. Label minimum 
ratio count was set to 2, peptides for quantification was set to unique and razor and re-quantify to allow identifi-
cation and quantification of proteins in groups for LFQ analysis.
First, MaxQuant were corrected for systematic inaccuracies of measured peptide masses and corresponding 
retention times of extracted peptides from the raw data. Then for peptide identification, mass and intensity of the 
peptide peaks in mass spectrometry (MS) spectrum were detected and assembled into three-dimensional (3D) 
peak hills over the m/z retention time plane, which was filtered by applying graph theory algorithms to identify 
isotope patterns. High mass accuracy was achieved by weighted averaging and through mass recalibration by sub-
tracting the determined systematic mass error from the measured mass of each MS isotope pattern. Peptide and 
fragment masses (in case of an MS/MS spectrum) were searched in an organism-specific sequence database and 
then were scored by a probability-based approach termed peptide score. For limiting a certain number of peak 
matches by chance, a target-decoy-based false discovery rate (FDR) approach was utilized. The FDR was deter-
mined using statistical methods that account for multiple hypotheses testing. Also, the organism-specific database 
search includes not only the target sequences but also their reverse counterparts and contaminants, which help 
to determine a statistical cut-off for acceptable spectral matches. The assembly of peptide hits into protein hits to 
identify proteins is the next step, in which each identified peptide of a protein contributes to the overall identifica-
tion accuracy. Also, an FDR-controlled algorithm called matching between runs was incorporated, which enables 
the MS/MS free identification of MS features in the complete data set for every single measurement, leading to an 
increase in the number of quantified proteins per sample40.
Perseus analysis pipeline. The MaxQuant software generated output file “proteingroups.txt” was utilized 
for Pearson correlation, clustering and statistical analysis using Perseus software version 1.6.1.124. Unverified hier-
archical clustering of the LFQ values was carried out based on Euclidean distances on the Z-scored among mean 
values. For statistical analysis, two-samples t-test-based statistics with P < 0.05 was applied on Log2 transformed 
LFQ values and the minimum number of values “in at least one group” was three to assert proteins regulation as 
significant for the specific groups43,44.
Functional classification and pathway analysis. Proteins determined to be differentially expressed 
based on the data in LFQ experiments were tabularize in Excel, and their gene names were used for functional 
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annotation and pathways analysis. The DEPs were connecting to at least one annotation term each within the 
molecular function (MF), biological process (BP) and cellular component (CC) classes. In this study, DAVID 
Bioinformatics Resources 6.8 (https://david.ncifcrf.gov/)45 and GO Enrichment Analysis (http://geneontology.
org/page/go-enrichment-analysis) were used for gene annotation of DEPs.
The protein list was uploaded into DAVID and searched for enrichment for GOBP term, and the results were 
filtered based on threshold count ≥2 and p-value <0.05.
Protein-protein network analysis. The protein-protein network analysis is a wide-ranging approach to 
know the annotation of desire proteome46. The functional network analysis is helpful to discover a drug, to under-
stand metabolic pathways and to predict or develop genotype-phenotype associations47,48. We have performed the 
protein-protein network analysis for all DEPs using STRING 10.5 database (https://string-db.org/). STRING tool 
classified the proteins according to the Gene Ontology (GO) categories such as biological process (BP), molecular 
function (MF), Cellular Component (CC) and KEGG (Kyoto Encyclopedia of Genes and Genomes database) 
pathways49. The tool Venny 2.1 (http://bioinfogp.cnb. csic.es/tools/venny/) was used to generate Venn diagrams.
Statistical analysis. All numeric values were expressed as the mean ± standard deviation (SD) for the 
respective groups. Statistical analyses were performed using the MaxQuant software (http://www.maxquant.org). 
Student t-tests and Benjamini–Hochberg corrections (FDR) was used. A p-value of less than 0.05 was considered 
as a significant.
Data Availability
The dataset generated during this work have been deposited to the ProteomeXchange Consortium via PRIDE 
partner repository with the dataset identifier PXD010757.
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